Sequencing one Topo-1 payload ADC directly after another yields diminished patient benefit, even when alternating surface targets like TROP-2 and HER2. Dr. Tolaney notes that while some patients still respond, resistance appears predominantly driven by the chemotherapy payload rather than target mutations.
Classic ADCs depend on cellular internalization and subsequent membrane permeability to exert bystander cell killing. Sacituzumab govitecan operates differently by releasing its SN-38 payload directly into the extracellular tumor microenvironment prior to entering cancer cells, effectively targeting heterogenous tumors lacking uniform expression.
ASCENT-03 did not demonstrate early overall survival separation because 80% of control patients crossed over to sacituzumab upon disease progression. In contrast, Tropion Breast-02 prohibited structured crossover, allowing datopotamab deruxtecan to demonstrate statistically significant improvements across both progression-free and overall survival endpoints.
Sacituzumab govitecan and datopotamab deruxtecan display nearly identical progression-free survival hazard ratios against chemotherapy in PD-L1-negative mTNBC. Clinicians should differentiate based on specific toxicity profiles, weighing datopotamab's mucositis and mandated ocular examinations against sacituzumab's higher frequencies of severe neutropenia and diarrhea.
Sequencing recommendations for HER2-low metastatic breast cancer diverge according to hormone receptor status. Data indicates that patients with hormone receptor-positive disease benefit most from receiving T-DXD prior to a TROP-2 ADC, whereas patients with triple-negative tumors achieve superior outcomes by starting with a TROP-2 ADC before T-DXD.
Around 5% to 10% of patients receiving trastuzumab deruxtecan continue to suffer from significant emesis despite triple- or quadruple-drug antiemetic regimens. In these refractory cases, adding 2.5 milligrams of olanzapine at bedtime effectively controls acute gastrointestinal distress and helps patients avoid dose modifications.
